DrugPatentWatch Database Preview
ERAXIS Drug Profile
When do Eraxis patents expire, and when can generic versions of Eraxis launch?
Eraxis is a drug marketed by Vicuron and is included in one NDA. There are three patents protecting this drug.
This drug has sixty-seven patent family members in twenty-nine countries.
The generic ingredient in ERAXIS is anidulafungin. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the anidulafungin profile page.
Summary for ERAXIS
| International Patents: | 67 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 35 |
| Clinical Trials: | 11 |
| Patent Applications: | 1,423 |
| Drug Prices: | Drug price information for ERAXIS |
| DailyMed Link: | ERAXIS at DailyMed |
Generic Entry Opportunity Date for ERAXIS
Generic Entry Date for ERAXIS*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;IV (INFUSION) |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for ERAXIS
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Texas Southwestern Medical Center | Phase 4 |
| Texas Tech University Health Sciences Center | Phase 4 |
| National Center for Research Resources (NCRR) | Phase 4 |
Pharmacology for ERAXIS
| Drug Class | Echinocandin Antifungal |
Synonyms for ERAXIS
| 166663-25-8 |
| 663A258 |
| 9HLM53094I |
| AC1L4YAI |
| AKOS030526640 |
| AN-5571 |
| Anidulafungin |
| Anidulafungin (LY303366) |
| Anidulafungin [USAN:INN:BAN] |
| Anidulafungin [USAN:INN] |
| Anidulafungina |
| Anidulafungine |
| Anidulafunginum |
| AT-36943 |
| BDBM50417554 |
| C58H73N7O17 |
| CHEBI:55346 |
| CHEMBL264241 |
| DB00362 |
| Ecalta |
| Echinocandin B, 1-((4R,5R)-4,5-dihydroxy-N(sup 2)-((4'-(pentyloxy)(1,1':4',1'-terphenyl)-4-yl)carbonyl)-L-ornithine)- |
| Echinocandin B, 1-((4R,5R)-4,5-dihydroxy-N2-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-L-ornithine) |
| Echinocandin B, 1-((4R,5R)-4,5-dihydroxy-N2-((4"-(pentyloxy)(1,1':4',1"-terphenyl)-4-yl)carbonyl)-L-ornithine) |
| J-010304 |
| LS-63738 |
| LY-303366 |
| LY303366 |
| MolPort-006-167-527 |
| N-((2R,6S,9S,11R,12R,14aS,15S,16S,20S,23S,25aS)-23-((1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl)-2,11,12,15-tetrahydroxy-6,20-bis((R)-1-hydroxyethyl)-16-methyl-5,8,14,19,22,25-hexaoxo |
| N-[[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-tetrahydroxy-bis[(1R)-1-hydroxyethyl]-methyl-hexaoxo-[?]yl]-4-[4-(4-pentoxyphenyl)phenyl]benzamide |
| NCGC00386349-01 |
| s4286 |
| SCHEMBL38292 |
| SW222238-1 |
| tetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl)-4''-(pentyloxy)-[1,1':4',1''-terphenyl]-4-carboxamide |
| UNII-9HLM53094I |
| V-Echinocandin |
| VER-002 |
| Z-3192 |
US Patents and Regulatory Information for ERAXIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vicuron | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-001 | Feb 17, 2006 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Vicuron | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-002 | Nov 14, 2006 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Vicuron | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-001 | Feb 17, 2006 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ERAXIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Vicuron | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-001 | Feb 17, 2006 | Start Trial | Start Trial |
| Vicuron | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-002 | Nov 14, 2006 | Start Trial | Start Trial |
| Vicuron | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-002 | Nov 14, 2006 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ERAXIS
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 1080926 | Start Trial |
| Japan | 4755464 | Start Trial |
| Norway | 930948 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ERAXIS
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0561639 | SPC/GB08/016 | United Kingdom | Start Trial | PRODUCT NAME: ANIDULAFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/416/001 20070920 |
| 0561639 | C300334 | Netherlands | Start Trial | PRODUCT NAME: ANIDULAFUNGIN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/07/416/001 20070920 |
| 0561639 | CA 2008 00017 | Denmark | Start Trial | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
